|
Neoplasm Metastasis
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
<b>Results:</b> We found that high MCT1 expression correlated with lymph node and distant metastasis.
|
30026847 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>Background</i>: Monocarboxylate transport protein 1 (MCT1) has been defined as a critical regulator in tumor energy metabolism, but bibliometric analysis of MCT1 research is rare.
|
30934693 |
2019 |
|
Adenocarcinoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i> effects on extracellular flux via glycolysis and mitochondrial stress tests suggest that candidate compounds 3 and 9 disrupt glycolysis and OxPhos efficiently in MCT1 expressing colorectal adenocarcinoma WiDr and MCT4 expressing triple negative breast cancer MDA-MB-231 cells.
|
31040927 |
2019 |
|
Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>In vivo</i>, AZD3965 caused lactate accumulation in the Raji Burkitt's lymphoma model and significant tumor growth inhibition.
|
29050199 |
2017 |
|
Adult Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>In vivo</i>, AZD3965 caused lactate accumulation in the Raji Burkitt's lymphoma model and significant tumor growth inhibition.
|
29050199 |
2017 |
|
Childhood Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>In vivo</i>, AZD3965 caused lactate accumulation in the Raji Burkitt's lymphoma model and significant tumor growth inhibition.
|
29050199 |
2017 |
|
Colorectal Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CRC cell exposure to acetate upregulates the expression of MCT1, MCT4 and CD147, while promoting MCT1 plasma membrane localization.
|
28874966 |
2016 |
|
Glioblastoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
MCT 1 and 2 were the primary isoforms expressed in human glioblastoma multiforme and glioma-derived cell lines.
|
15574223 |
2004 |
|
Glioblastoma Multiforme
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
MCT 1 and 2 were the primary isoforms expressed in human glioblastoma multiforme and glioma-derived cell lines.
|
15574223 |
2004 |
|
Sarcoidosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CMA1 polymorphisms do not influence radiographic evolution in Dutch sarcoidosis patients, nor do they predispose to cardiac or skin involvement in Japanese patients.
|
16446531 |
2006 |
|
Diffuse Large B-Cell Lymphoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
MCT-1 is over-expressed in a subset of diffuse large B-cell lymphoma (DLBCL), a common form of Non-Hodgkin's Lymphoma (NHL).
|
16815567 |
2006 |
|
Lymphoma, Non-Hodgkin
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MCT-1 is over-expressed in a subset of diffuse large B-cell lymphoma (DLBCL), a common form of Non-Hodgkin's Lymphoma (NHL).
|
16815567 |
2006 |
|
T-Cell Lymphoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
MCT-1 is an oncogene that was initially identified in a human T cell lymphoma and has been shown to induce cell proliferation as well as activate survival-related pathways.
|
16982740 |
2006 |
|
Inflammatory Bowel Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
MCT1 messenger RNA (mRNA) and protein levels were markedly decreased in inflamed colonic mucosa of IBD patients and rats.
|
18054563 |
2007 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCT1 expression was detected exclusively in nonhypoxic regions of human cancer biopsy samples, and in combination, these data suggest that MCT1 inhibition holds potential as a novel cancer therapy.
|
19033652 |
2008 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCT1 expression was detected exclusively in nonhypoxic regions of human cancer biopsy samples, and in combination, these data suggest that MCT1 inhibition holds potential as a novel cancer therapy.
|
19033652 |
2008 |
|
Gastrointestinal Stromal Tumors
|
0.010 |
AlteredExpression
|
group |
BEFREE |
MCT1, MCT2 and MCT4 were highly expressed in GISTs.
|
22281667 |
2012 |
|
insulinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MCT1 protein was detected in three of four additional insulinomas.
|
23073708 |
2013 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCT1 expression is associated with developing a new therapeutic approach for cancer.
|
24012639 |
2014 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCT1 expression is associated with developing a new therapeutic approach for cancer.
|
24012639 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
|
26045776 |
2015 |
|
Epithelial ovarian cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
|
26045776 |
2015 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MCT1 and MCT4 (messenger RNA, protein) were robustly expressed in all PDAC lines, localizing to the plasma membrane.
|
26765963 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
|
26876179 |
2016 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
|
26876179 |
2016 |